

**12th Australian Influenza Symposium**  
**1-2 November 2017, Doherty Institute, Melbourne, Australia**

**Program Day 1: Wednesday, 1 November**

<b>0850</b>	<b>Welcome and meeting logistics: Ian Barr, WHO CC, Melbourne, VIC</b>	
<b>Plenary Session 1</b>		<b>Chair: Kanta Subbarao, WHO CC, Melbourne, VIC</b>
<b>0900</b>	<b>Yuelong Shu, Sun Yat-sen University, China</b>	The genesis and evolution of H7N9 viruses: from LPAI to HPAI
<b>0930</b>	<b>Malik Peiris, The University of Hong Kong, Hong Kong</b>	Pandemic risk assessment of influenza viruses
<b>1000</b>	<b>Anice Lowen, Emory University, Atlanta, GA</b>	Role of RNA packaging signals in directing influenza A virus reassortment
<b>1030</b>	<i>Morning tea</i>	
<b>Plenary Session 2: Childhood, Maternal and elderly influenza vaccination strategies</b>		<b>Chair: Hannah Moore, Telethon Kids Institute, Perth, WA</b>
<b>1100</b>	<b>Saad Omer, Emory University, Atlanta, GA</b>	Maternal Influenza Immunization
<b>1130</b>	<b>Annette Regan, Curtin University, Perth, WA</b>	The Pregnancy Vaccine Effectiveness Network (PREVENT): A multi-country pregnancy cohort estimating influenza vaccine effectiveness against hospitalization
<b>1150</b>	<b>Helen Marshall, The University of Adelaide, SA</b>	Optimising influenza immunisation in pregnancy
<b>1210</b>	<b>Ben Cowling, The University of Hong Kong, Hong Kong</b>	Influenza vaccination strategies in older adults
<b>1230</b>	<i>Lunch</i>	
<b>Plenary Session 3: Hot topics</b>		<b>Chair: James McCaw, The University of Melbourne, VIC</b>
<b>1315</b>	<b>Jemma Geoghegan, Macquarie University, Sydney, NSW</b>	Continental synchronicity of human influenza virus epidemics despite climactic variation
<b>1335</b>	<b>Rob Moss, The University of Melbourne, VIC</b>	Epidemic forecasts as a (potential) tool for public health
<b>1355</b>	<b>Philip Britton, The University of Sydney, NSW</b>	Influenza associated neurological disease in Australian Children: a seasonal challenge.
<b>1415</b>	<b>Kristine Macartney, National Centre for Immunisation Research and Surveillance (NCIRS), Sydney, NSW</b>	From infants to centenarians: actively monitoring influenza vaccine safety in Australia using AusVaxSafety
<b>1435</b>	<b>Eddie Holmes, The University of Sydney, NSW</b>	Diversity and Evolution of Influenza Viruses in Novel Animal Systems
<b>Roundtable Discussion</b>		<b>Chair: Ian Barr, WHO CC, Melbourne, VIC</b>
<b>1500</b>	<b>For discussion:</b> What can we do to reduce the impact of seasonal influenza epidemics (especially H3) in Australia? <b>Panelists:</b> Kristine Macartney, Ben Cowling, Robert Booy, Chris Blyth, Helen Marshall, Paul van Buynder	
<b>1530</b>	<i>Afternoon tea</i>	
<b>Workshop 1: Epidemiology</b>		<b>Chair: Sheena Sullivan, WHO CC, Melbourne, VIC</b>
<b>1600</b>	<b>Robert Booy, National Centre for Immunisation Research &amp; Surveillance, Sydney, NSW</b>	Using individual level data to analyse post-vaccination fever, antipyretic use and influenza vaccine immunogenicity in children
<b>1615</b>	<b>Surendra Karki, The University of New South Wales, Sydney, NSW</b>	Association between body mass index and laboratory confirmed influenza in middle aged and older adults: a prospective cohort study
<b>1630</b>	<b>Christopher Blyth, University of Western Australia / Princess Margaret Hospital, Perth, WA</b>	Hospitalised Influenza in Australian Children: a 12 year birth cohort study to assess the burden of disease and impact of comorbidities and vaccination
<b>1645</b>	<b>Annette Fox, The University of Melbourne, VIC</b>	The impact of prior immunity on seasonal influenza vaccine responses in an influenza vaccine-naïve Vietnamese cohort
<b>1700</b>	<b>Madeline Hall, Queensland Health, Brisbane, QLD</b>	Improving health care worker influenza vaccine uptake through a Nurse Practitioner led vaccination service
<b>1715</b>	<b>Daniel Norman, University of New South Wales, Sydney, NSW</b>	Parental attitudes and practices for influenza vaccination in high-risk children
<b>1730</b>	<b>Day 1 concludes – Drinks and finger food at the Doherty Institute</b>	

**12th Australian Influenza Symposium**  
**1-2 November 2017, Doherty Institute, Melbourne, Australia**

**Program Day 2: Thursday, 2 November**

<b>Plenary Session 4: Industry – Commercial updates</b>		<b>Chair: Andrea Forde</b>
0840	Philippe Buchy, GSK Vaccines Asia Pacific, Singapore	Why vaccinating children against influenza?
0900	Steve Rockman, Seqirus Ltd, Melbourne, VIC	MDCK Cells as a substrate for influenza virus isolation and vaccination
0920	Christian Felter, Sanofi Pasteur, Sydney, NSW	Overview of high-dose influenza vaccine and its clinical data
0940	Sean Parsons, Ellume Pty Ltd, Brisbane, QLD	Is the world ready for a smart-phone connected consumer flu test? Demonstration and clinical data presentation of the Ellume Home Flu Test
1000	Lori Brown, The University of Melbourne, VIC	A new concept in the design of antiviral drugs for influenza
1020	Kanta Subbarao, WHO CC, Melbourne, VIC	The role of monoclonal antibodies against the influenza virus haemagglutinin in prophylaxis and treatment of infection
1045	<i>Morning tea</i>	
<b>Workshop 2: Research</b>		<b>Chair: Sarah Londrigan, The University of Melbourne, VIC</b>
1115	Angela Pizzolla, The University of Melbourne, VIC	Nasal tissue resident memory CD8+ T cells prevent pulmonary influenza A virus infection
1130	Oanh Nguyen, The University of Melbourne, VIC	Human T follicular helper cell dynamics and TCR profiles during acute seasonal influenza virus infection and immunization
1145	Jeremy Rossman, University of Kent, Canterbury, UK	Influenza A virus subverts the host autophagy response to facilitate virus assembly and immune evasion
1200	Jen-Ren Wang, National Cheng Kung University, Taiwan	Two evolutionally identified substitutions in influenza A nucleoprotein affect viral translation and replication
1215	Benjamin Bailly, Griffith University, Brisbane, QLD	Discovery and characterisation of next-generation influenza virus neuraminidase inhibitors
1230	Mathieu Fourment, University of Technology Sydney, NSW	The Impact of Migratory Flyways on the Spread of Avian Influenza Virus in North America
1245	Jeff Butler, CSIRO – AAHL, Geelong, VIC	Rapid emergence and global spread of H5Nx HPAI viruses, what does this mean for Australia?
1300	<i>Lunch</i>	
<b>Plenary Session 5</b>		<b>Chair: Chris Blyth, University of Western Australia / Princess Margaret Hospital, Perth, WA</b>
1345	Saad Omer, Emory University, Atlanta, GA	Interventions to Increase Influenza Vaccine Acceptance
1415	Anice Lowen, Emory University, Atlanta, GA	Incomplete viral genomes drive abundant influenza A virus reassortment
1445	Malik Peiris, The University of Hong Kong, Hong Kong	MERS
1515	<i>Afternoon tea</i>	
<b>Joint session with the Australian Respiratory Virology Meeting</b>		<b>Chairs: Reena Ghildyal, University of Canberra &amp; Kirsten Spann, Queensland University of Technology</b>
1545	Welcome	
1550	Kim Mulholland, MCRI Royal Children's Hospital, Melbourne, VIC	Respiratory Syncytial Virus Vaccines
1620	Hannah Moore, Telethon Kids Institute, Perth, WA	Uncovering the epidemiology of Respiratory Syncytial Virus through record linkage
1640	Nigel Crawford, MCRI Royal Children's Hospital, Melbourne, VIC	RSV surveillance @ RCH Melbourne: WHO Pilot study
1700	John Sebastian Eden, The University of Sydney, NSW	The phylodynamics of respiratory syncytial virus in New South Wales, Australia between 2010-2016
1720	Keith Chappell, The University of Queensland, Brisbane, QLD	Engineering subunit vaccines to provide protection against Respiratory Syncytial virus
1745	Joint session and Australian Influenza Symposium concludes	